SphingoGene, Inc. is focused on commercialization of small molecule therapeutics that modify ceramide metabolism to overcome resistance to chemo and radiation therapy and promote apoptosis in cancer cells.  Ceramide is a "tumor suppressor sphingolipid" involved in regulation of cell death.  SphingoGene, Inc.'s molecules are rationally designed and proven to inhibit enzymes that create resistance to conventional cancer therapies.  Their goal is to utilize these small molecules in combination with "standard of care" radiation or chemotherapy to enhance cancer cell death.   SphingoGene, Inc. products and services include:

• Commercial Lipidomic Services
• Molecular diagnostic to predict patient response
• Combination therapy for standard of care
• Therapies in cancer patients (chemo, radiation and gene therapy)

To learn more about SphingoGene, please visit their website at: http://sphingogene.com